It is not suitable for people with type 1 diabetes, a history of pancreatitis, or those already using a GLP-1 agonist
The result: telomerase catalytic subunit expression was reactivated, enzyme activity increased, and telomere lengthening occurred, effectively extending the cells proliferative capacity from ~34 to over 44 passages [1]
SGLT-2i=sodium-glucose cotransporter-2 inhibitor
Despite the significant survival advantage it confers, ADT is associated with numerous adverse effects including increased risk for cardiovascular diseases, diabetes, sexual dysfunction, cognitive, and mood dysfunction, and sleep disturbance (Gonzalez et al., 2018